一般演題（口演）15 EGFR遺伝子変異陽性肺癌（臨床試験）

[O15-6] A randomized study of afatinib for 8 months switching to osimertinib in EGFR-mutated NSCLC（YAMATO）

^○Toshihide Yokoyama¹, Hiroshige Yoshioka², Atsushi Nakamura³, Toshihiro Misumi⁴, Hidetoshi Itani⁵, Motoko Tachihara⁶, Kaoru Tanaka⁷, Hiroaki Akamatsu⁸, Akira Ono⁹, Toshiyuki Harada¹⁰, Ken Masubuchi¹¹, Yuki Misumi¹², Satoru Miura¹³, Junko Tanizaki^7,14, Shuji Murakami¹⁵, Takehito Shukuya¹⁶, Hideki Ishikawa¹⁷, Nobuyuki Yamamoto⁸, Hiroaki Okamoto¹², Takayasu Kurata² (1.Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan, 2.Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka-Hirakata, Japan, 3.Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan, 4.Department of Data Science, National Cancer Center Hospital East, Tokyo, Japan, 5.Department of Respiratory Medicine, Japanese Red Cross Ise Hospital, Ise, Japan, 6.Division of Respiratory Medicine, Kobe University Hospital, Kobe, Japan, 7.Department of Medical Oncology, Kindai University Hospital, Osaka-Sayama, Japan, 8.Internal Medicine III, Wakayama Medical University, Wakayama, Japan, 9.Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan, 10.Respiratory Disease Center, Independent Administrative Institution, Organization for Promotion of Regional Medical Functions Hokkaido Hospital, Hokkaido, Japan, 11.Department of Respiratory Medicine, Gunma Prefectural Cancer Center, Gunma, Japan, 12.Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, Yokohama, Japan, 13.Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan, 14.Department of Medical Oncology, Kishiwada City Hospital, Osaka-Kishiwada, Japan, 15.Department of Thoracic Oncology, Kanagawa Cancer Center, Kanagawa, Japan, 16.Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan, 17.Department of Molecular-Targeting Cancer Prevention, Kyoto Prefectural University of Medicine, Kyoto, Japan)

アンコール演題